Research Topics
| M OrdituraSummaryAffiliation: Second University of Naples Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institution phase II trialsM Orditura
Department of Clinical and Experimental Medicine and Surgery F Magrassi A Lanzara, Second University of Naples School of Medicine, Naples, Italy
Dis Esophagus 25:130-6. 2012..0157 and P= 0.0212, respectively). In our series, complete responder patients had a significant longer survival probability after treatment when compared to patients with partial response or stable disease...
Detection of erbB2 copy number variations in plasma of patients with esophageal carcinomaImmacolata Andolfo
CEINGE, Centro di Ingegneria Genetica e Biotecnologia Avanzate, Naples, Italy
BMC Cancer 11:126. 2011..Here, we sought to isolate cell-free DNA released into the plasma of patients with esophageal carcinoma, to analyze copy number variations of marker genes in the search for early detection of tumor progression...- Adjuvant chemoradiotherapy in patients with stage III or IV radically resected gastric cancer: a pilot studyMichele Orditura
Division of Medical Oncology, F Magrassi A Lanzara Department of Clinical and Experimental Medicine and Surgery, Second University of Naples School of Medicine, c o II Policlinico, Via Pansini 5, Naples, Italy
Arch Surg 145:233-8. 2010..We assessed the feasibility and toxic effects of chemoradiotherapy as adjuvant treatment in locally advanced gastric cancer... 
Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysisMichele Orditura
Division of Medical Oncology, F Magrassi A Lanzara Department of Clinical and Experimental Medicine, Second University of Naples School of Medicine, c o II Policlinico, 80131 Naples, Italy
Oncol Rep 21:1023-8. 2009..Skin toxicity was confirmed as the only clinical variable able to predict the response to cetuximab...- Chemoradiotherapy as adjuvant treatment of gastric cancerM Orditura
Department of Medical Oncology, F Magrassi and A Lanzara, Second University of Naples School of Medicine, Naple, Italy
Ann Oncol 18:vi133-5. 2007..However, many questions remain to evaluate; first of all the toxicity of this approach and its efficacy after adequate surgery... - Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal massMichele Orditura
Cattedra di Oncologia Medica, Seconda Università degli Studi di Napoli Ospedale Da Procida, Salerno, Naples, Italy
World J Surg Oncol 5:42. 2007..Stomach is the most frequent site where hepatoid adenocarcinoma occurs, although it has been described in many other organs. On the other side, liposarcoma is a rare, malignant tumor that develops from fat cells... - Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma. Southern Italy Cooperative Oncology GroupP Comella
Medical Oncology A, National Tumour Institute, Naples, Italy
Ann Oncol 11:461-8. 2000.... - Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II studyM Orditura
Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale 'F Magrassi e A Lanzara Cattedra di Oncologia Medica, Naples, Italy
Ann Oncol 17:1529-32. 2006..CONCLUSIONS: The combination of docetaxel and capecitabine at the doses and schedule investigated in this study is safe, but does not show significant activity in untreated patients with advanced gastric cancer... - Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survivalM Orditura
F Magrassi Department of Clinical and Experimental Medicine, Second University of Naples School of Medicine, Italy
Cancer Immunol Immunother 49:530-6. 2000..In conclusion, determination of pre-treatment IL-2 serum levels was shown to be of independent prognostic utility in patients with advanced NSCLC; therefore, its possible use for prediction of outcome is proposed... - A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancerF De Vita
Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery F Magrassi e A Lanzara, Second University of Naples, Via Pansini 5, Naples 80131, Italy
Br J Cancer 104:427-32. 2011..Preoperative chemoradiotherapy (CRT) improves the survival of patients with oesophageal cancer when compared with surgery alone... - Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicatorF De Vita
Division of Internal Medicine, F Magrassi Department of Clinical and Experimental Medicine, Second University of Naples School of Medicine, Naples, Italy
J Interferon Cytokine Res 21:45-52. 2001..In conclusion, this study showed that IL-6 serum levels were elevated in advanced gastrointestinal cancer patients and correlated with both OS and TTP. However, they were shown not to be an independent prognostic factor... - Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study)F De Vita
Division of Medical Oncology, Second University, Napoli, Italy
Ann Oncol 18:1354-8. 2007..This randomized, multicenter, phase III trial evaluated the efficacy and safety of the combination of epirubicin, leucovorin, 5-fluorouracil and etoposide (ELFE regimen) as adjuvant therapy for radically resected gastric cancer patients... - A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patientsF De Vita
Division of Medical Oncology, F Magrassi and A Lanzara Department of Clinical and Experimental Medicine, Second University of Naples School of Medicine, Naples, Italy
Br J Cancer 92:1644-9. 2005..FOLFOX-4 is an active and well-tolerated chemotherapy. Response rate (RR), TTP and OS were comparable with those of other oxaliplatin-based regimens, suggesting a role for this combination in gastric cancer... - Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancerG Galizia
Division of Surgery, F Magrassi A Lanzara Department of Clinical and Experimental Medicine and Surgery, Medical and Surgical Oncology and Clinical Immunology, Second University of Naples School of Medicine, Naples, Italy
Oncogene 26:3654-60. 2007..Furthermore, a series of phase III clinical trials are currently evaluating the combination of cetuximab with standard chemotherapy regimens in the first-line treatment chemotherapy-naïve patients with metastatic CRC... - Gemcitabine plus epirubicin in advanced pancreatic cancer: a phase II multicenter trialG P Ianniello
Division of Medical Oncology, G Rummo Hospital, Benevento, Italy
Oncol Rep 8:1111-5. 2001..In conclusion, the GEM plus EPI regimen represent a feasible approach for improvement of clinical benefit in advanced pancreatic cancer patients, but confirmatory investigations are required... - Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancerF Iovino
Division of Oncological Surgery, Second University of Naples, Naples, Italy
Cancer Invest 26:250-5. 2008..041) and circulating VEGF levels (p = 0.047). The results confirm that in primary endocrine-positive breast cancer serum VEGF levels are elevated and show a positive relationship with tumor VEGF and p53 overexpression... - Adjuvant chemotherapy of gastric cancer: which regimens?F De Vita
Division of Medical Oncology, F Magrassi and A Lanzara Department of Clinical and Experimental Medicine, Second University of Naples, School of Medicine, Naples, Italy
Ann Oncol 16:iv102-105. 2005..Therefore, at present the routine use of adjuvant therapy should be regarded as an investigational approach. Improved clinical trial designs with standardized surgical techniques and the incorporation of newer active drugs are needed... - Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapyF Ciardiello
Cattedra di Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Naples, Italy
Ann Oncol 17:vii109-14. 2006..This review focuses on the preclinical rationale of combining targeted agents such as EGFR and VEGF inhibitors in the treatment of cancer and on the clinical trials that have emerged from these studies... - Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic targetF De Vita
Division of Medical Oncology, F Magrassi and A Lanzara Department of Clinical and Experimental Medicine and Surgery, Second University of Naples School of Medicine, c o II Policlinico, Via S Pansini 5, Naples, Italy
Cancer Treat Rev 36:S11-5. 2010..Based on these results trastuzumab combined with a cisplatin and fluoropyrimidine regimen appear the new reference treatment for HER-2 positive metastatic gastric cancer... - Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapyE Martinelli
Dipartimento Medico Chirurgico di Internistica Clinica, Seconda Universita degli Studi di Napoli, Naples, Italy
Clin Exp Immunol 158:1-9. 2009..In this review, attention is focused on cetuximab and panitumumab, two mAb introduced recently into clinical practice for treatment of metastatic colorectal and head and neck cancer which target the external part of EGFR... - Neo-adjuvant and adjuvant chemotherapy of gastric cancerF De Vita
Division of Medical Oncology, Surgical Oncology, F Magrassi and A Lanzara, Department of Clinical and Experimental Medicine, Second University of Naples School of Medicine, Naples, Italy
Ann Oncol 18:vi120-3. 2007..On the contrary, neo-adjuvant chemotherapy has shown promising results as suggested by the final results of UK Medical Research Council Adjuvant Gastric Infusional Chemotherapy trial... - Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancerF Ciardiello
Cattedra di Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Via S Pansini 5, 80131 Naples, Italy
Br J Cancer 94:1604-9. 2006..Complete plus partial responses correlated with oestrogen receptor (ER) status, since they occurred in 19 out of 27 (70%) patients with ER-positive tumours as compared to three out of 14 (21%) patients with ER-negative tumours (P=0.01)... - Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patientsF De Vita
Department of Clinical and Experimental Medicine F Magrassi, Second University of Naples School of Medicine, Naples, Italy
Chest 117:365-73. 2000..To investigate the prognostic significance of interleukin (IL)-10 serum levels in advanced non-small cell lung cancer (NSCLC) patients... - Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patientsP Comella
Medical Oncology A, National Tumour Institute, Via M Semmola, 80131 Naples, Italy
Br J Cancer 86:1871-5. 2002.... - Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitorsM P Morelli
Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale F. Magrassi e A. Lanzara, , Napoli, Italy
Ann Oncol 16:iv61-68. 2005..CONCLUSIONS: This study provides a rationale for the evaluation of a potentially synergistic sequence of cytotoxic drugs and EGFR inhibitors in a clinical setting...